The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance

Autor: Harrison Sicheng Lin, Qiang Ding, Zsuzsanna Lichner, Sung Sun Kim, Rola Saleeb, Mina Farag, Ashley Di Meo, Pamela Plant, Mirit Kaldas, Georg Arnold Bjarnason, George Makram Yousef

Publikováno v: Journal of Clinical Medicine; Volume 11; Issue 2; Pages: 369
Journal of Clinical Medicine, Vol 11, Iss 369, p 369 (2022)
Journal of Clinical Medicine

With sunitinib treatment of metastatic renal cell carcinoma, most patients end up developing resistance over time. Recent clinical trials have shown that individualizing treatment protocols could delay resistance and result in better outcomes. We dev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb004b4013df709ee867e631daeaa79f